Home
Corporate Profile
Respiratory Disease
Product Development
News & Events
Investors & Partnering
- Why invest in SolAeroMed
Contact Us
Recruiting Cystic Fibrosis and non CF Bronchiectasis Patients
SolAeroMed S-1226 COVID-19 clinical trial

Home / News / S1226 Portable Delivery Advanced Design Concept

News

S1226 Portable Delivery Advanced Design Concept

June 27, 2018/ / News

We have now completed a $150,000 grant with Calgary based SAIT, which build on the earlier work by Melbourne based Hydrix. The result is a more advanced design for our portable S1226 delivery device.

Facebook
Twitter
Google+
Pinterest

SolAeroMed is actively recruiting non CF bronchiectasis patients in Calgary

The global pandemic has compromised many clinical trials, including SolAeroMed’s ongoing Phase II Bronchiectasis trial. Recruitment of non CF bronchiectasis patients is gaining lost momentum

Publication of S1226 clinical results in medRxiv Dec 13 2021.

SolAeroMed clinicians have published S1226 clinical trial results in CF and non CF Bronchiectasis, where positive safety and efficacy signals are described across all dosing levels and in all...

Presentation at ISAM May 2021, Boise Idaho

SolAeroMed CEO presented clinical study results in Bronchiectasis at the International Socieity of Aerosol Medicine meeting in Boise Idaho in May 2021. Ensuing discussion led to 3rd party interest...

News

S1226 Portable Delivery Advanced Design Concept

Related posts

SolAeroMed is actively recruiting non CF bronchiectasis patients in Calgary

Publication of S1226 clinical results in medRxiv Dec 13 2021.

Presentation at ISAM May 2021, Boise Idaho